All In Biotech

Drug Trial Radar · NCT02203032

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

Last checked: Nov 20, 2026Latest source record: Sep 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 872 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

872

Actual

Start

Oct 7, 2014

Primary completion

Dec 25, 2015

Study completion May 24, 2016

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab.

Conditions

  • Psoriasis

Interventions

  • UstekinumabDrug

    45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.

  • GuselkumabDrug

    100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.

  • Placebo for ustekinumabDrug

    Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.

  • Placebo for guselkumabDrug

    Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40Time frame: Week 28 through Week 40

Locations

85 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Bakersfield, California

  • Site not named

    Los Angeles, California

  • Site not named

    Santa Monica, California

  • Site not named

    Coral Gables, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Alpharetta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Skokie, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Plainfield, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Boston, Massachusetts

  • Site not named

    Troy, Michigan

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Johnston, Rhode Island

  • Site not named

    Nashville, Tennessee

  • Site not named

    Arlington, Texas

  • Site not named

    Austin, Texas

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Webster, Texas

  • Site not named

    Norfolk, Virginia

  • Site not named

    Spokane, Washington

  • Site not named

    Fremantle, Australia

  • Site not named

    Victoria Park, Australia

  • Site not named

    Woden, Australia

  • Site not named

    Woolloongabba, Australia

  • Site not named

    Surrey, British Columbia, Canada

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Moncton, New Brunswick, Canada

  • Site not named

    Halifax, Nova Scotia, Canada

  • Site not named

    Ajax, Ontario, Canada

  • Site not named

    Richmond Hill, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.